Syngene International Ltd - 539268 - Intimation Of Audio Recording For Q1 FY23 Post Earnings Call.
Intimation of audio recording for Q1 FY23 post earnings call.21-07-2022
21-07-2022
Syngene International Ltd - 539268 - Voting Results Under Regulation 44(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Voting results under Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201521-07-2022
Syngene International Ltd - 539268 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
The consolidated Scrutinizer's Report on the remote e-voting and voting through Insta-poll on 29th AGM held on July 20, 2022.21-07-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the shareholders at the 29th Annual General Meeting ('AGM') held on July 20, 2022 approved the re-appointment of Ms. Sharmila Abhay Karve (DIN: 05018751) as the Independent Director on the Board of Directors of the Company, for a second term of five years commencing from the date of 29th AGM i.e. July 20, 2022.21-07-2022
Syngene International Ltd - 539268 - Shareholder Meeting / Postal Ballot-Outcome of AGM
With reference to the above-mentioned subject, we hereby enclose the proceedings of the 29th Annual General Meeting ('AGM') held on Wednesday, July 20, 2022 at 03:30 p.m. through video conferencing.21-07-2022
Syngene International Q1 PAT slips 4% to Rs 74 cr; revenue rises 8%
Contract manufacturing services firm Syngene International on Wednesday reported a 4 per cent decline in profit after tax to Rs 74 crore for the first quarter ended June 2022. The company had posted a PAT of Rs 77 crore in the April-June quarter of last fiscal. Its revenue from operations rose to Rs 644 crore in the first quarter against Rs 595 crore in the year-ago period, the company said in a statement. The first quarter results were against a strong quarter last year due to sales of Remdesivir, it added. Excluding the impact of Remdesivir, the underlying revenue from operations growth in the quarter stood at around 30 per cent year-on-year, it stated. "The first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. The contribution from the development and manufacturing services divisions drove the growth momentum against a low base in the previous year," Syngene International MD and CEO Jonathan Hunt ..20-07-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended June 30, 2022. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to September 30, 2022.20-07-2022
Q1FY23 Quarterly Result Announced for Syngene International Ltd.
Pharmaceuticals firm Syngene International Announced Q1FY23 Result : Syngene reports revenue from operations up 8% in the first quarter Company raises the annual revenue guidance from mid-teens to high teens. The Company reported quarterly revenue from operations up 8% year-on-year to Rs. 644 Cr; profit after tax for the quarter declined by 4% year-on-year to Rs 74 Cr. The first quarter results were against a strong quarter last year due to sales of COVID treatment, Remdesivir. Excluding the impact of Remdesivir, the underlying revenue from operations growth in the quarter was around 30% year-on-year. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, "A recent highlight was the signing of a 10- year agreement with Zoetis. The new agreement initially focuses on the commercial manufacturing of Librela®, a first-of-its-kind injectable monoclonal antibody used for the alleviation of pain associated with osteoarthritis in dogs. This is a major strategic step for our biologics business and gives us a pathway towards FDA and EMA regulatory approvals anticipated later this year These first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. The contribution from the Development and Manufacturing Services divisions drove the growth momentum against a low base in the previous year. The Dedicated Centers and Discovery Services divisions delivered continued growth. The decline in profit in the quarter compared to the same period last year was as expected given the strong sales of Remdesivir last year when India was in the midst of the second wave of the pandemic. No sales of Remdesivir were recorded in the first quarter this year.” Result PDF20-07-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Syngene reports revenue from operations up 8% in the first quarter'20-07-2022
Syngene International Ltd - 539268 - Unaudited Financial Results For The Quarter Ended June 30, 2022.
Unaudited Financial Results for the quarter ended June 30, 2022.20-07-2022